md-medicaldata


Go to content

Main menu:

 

 

 

 

 

 

 


PULMONARY THROMBOEMBOLISM CAUSED BY SHORT-TERM USAGE OF COMBINED ORAL CONTRACEPTIVES (COCS) IN A YOUNG WOMAN WITH NEWLY DETECTED HOMOCYSTEINEMIA: WHEN THE HARM OUTWEIGHS THE BENEFIT, RARE AND INTERESTING CASE REPORT /

PLUĆNI TROMBOEMBOLIZAM UZROKOVAN KRATKOTRAJNOM PRIMENOM KOMBINOVANE ORALNE KONTRACEPTIVNE TERAPIJE KOD MLADE ŽENE SA NOVOOTKRIVENOM HOMOCISTEINEMIJOM: KADA ŠTETA PREVAZIĐE KORIST, REDAK I ZANIMLJIV PRIKAZ SLUČAJA

Authors

 

Dmitrović Radmila1 , Lazović Biljana1, Simonović Isidora1, Gligorić Tamara2

1Clinical Hospital Center “Zemun“, Department of pulmonology
1Clinical Hospital Center “Zemun”, Department of radiology

 

UDK: 616.24-005.6/.7-055.2
615.256.5.065


The paper was received / Rad primljen: 09.08.2021.

Accepted / Rad prihvaćen: 19.08.2021.

 


Correspondence to:


Radmila Dmitrović
University Clinical Center „Zemun“
Belgrade, Serbia
Vukova 9, Zemun, 11080 Belgrade
Self-phone: +381601322400
e-mail: radadmitrovic94@gmail.com

 

 

Abstract

 

PTE and VTE are rare but serious side effects of COCs treatment, especially when they are associated with conditions that might lead to thrombosis. In our study, we presented the case of a 21-year-old nulligravida woman who developed PTE as a result of short-term endometriosis treatment with COCs therapy. The patient was hospitalized in the ICU and was given a heparin infusion to treat the severe PTE. A more thorough investigation revealed elevated homocysteine and LAC levels. Because of these high readings, it was agreed that warfarin medication would be continued once the condition stabilized. To provide the appropriate therapy, clinicians must consider all risk factors for the development of PTE.

 

Keywords:

pulmonary thromboembolism, oral contraceptives, homocysteinemia, lupus anticoagulant, warfarin

 

 

 

Sažetak

 

Plućna i venska tromboembolija su retke ali ozbiljne neželjene reakcije usled primene kombinovane oralne kontraceptivne terapije posebno ako su povezane sa faktorima koji mogu da dovedu do tromboze. Mi smo prezentovali slučaj žene stare 21 godinu (bez porođaja) koja je razvila masivnu plućnu tromboemboliju usled kratkotrajne primene oralne kontrceptivne terapije u cilju lečenja endometrioze. Bolesnica je primljena u jedinicu intenzivnog lečenja gde joj je ordinirana heparinska infuzija. Tokom hospitalnog lečenja kod bolesnice su dokazane povišene vrednosti homocisteina i lupus antikoagulans antitela. S obzirom na prethodno pomenute povišene vrednosti bolesnici je ordinirana terapija varfarinom nakon stabilizacije stanja.Neophodno je da lekari uzmu u obzir sve faktore rizika koji bi mogli da dovedu do plućne tromboembolije kako bi odabrali odgovarajuću terapiju.


Ključne reči:

plućna tromboembolija, oralni kontraceptivi, homocisteinemija, lupus antikoagulans, varfarin

 

 

 

 

References:

  1. Jeanine, uputstvo za pacijente. Agencija za lekove i medicinska sredstva. Available from: https://www.alims.gov.rs/wp-content/blogs.dir/2/files/lekovi/pil/2784-2008-12.pdf
  2. Jordan WM. Pulmonary embolism. Lancet. 1961;278 (7212):1146-1147.
  3. Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta analysis. BMJ2013;347:f5298.
  4. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–699. 
  5. Jeong Park M, Ho Jeon G. Pulmonary embolism in a healthy woman using the oral contraceptives containing desogestrel. Obstet Gynecol Sci. 2017;60(2):232-235.
  6. Sparić R, Lazović B, Stajić Z, Mazić S, Đelić M, Kadija S. Thromboembolic complications during pregnancy and delivery. Medicinski pregled. 2013;66(9-10):417-23.
  7. Suzuki A, Sanda N, Miyawaki Y, Fujimori Y, Yamada T, Takagi A, et al. Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem2010;285(18):13444–13453.
  8. Cohn DM, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: implications for testing. Semin Thromb Hemost. 2007;33(6):573-81.
  9. Obaid M, El-Menyar A, Asim M. Prevalence and outcomes of thrombophilia in patients with acute pulmonary embolism. Vasc Health Risk Manag. 2020;16:75-85.
  10. Biljana Lazovic, Rade Milic, Dzenana A Detanac, Vladimir Zugic, Džemail S Detanac, Mersudin Mulic. Pulmonary thromboembolism and role of factor V Leiden in its development-review of literature. Sanamed 2019;14(1):103-106.
  11. Lazovic B, Zugic V. Management of pulmonary embolism. Med Pregl 2018;71(9-10):329-334.
  12. Miniati M, Cenci C, Monti S, Poli D. Clinical presentation of acute pulmonary embolism: a survey of 800 cases. PloS One. 2012;7(2):e30891.
  13. Cohen AT, Dobromirski M, Gurwith MMP. Managing pulmonary embolism from presentation to extended treatment. Thromb Res. 2014;133(2):139-48.
  14. Aggarwal V, Nicolais CD, Lee A, Bashir R. Acute management of pulmonary embolism. Available from: https://www.acc.org/latest-in-cardiology/articles/2017/10/23/12/12/acute-management-of-pulmonary-embolism
  15. Rao Aroor A, Attar NR, Prakasha R, Dileep KS, Sharma R, Prakash PS. Hyperhomocysteinemia and pulmonary embolism without deep vein thrombosis in a young patient presenting as pneumonia- a rare case report. NUJHS. 2012. Available from: https://www.nitte.edu.in/journal/SepSplit/hapewdvt.pdf
  16. Undas A, Brozek J, Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost. 2005;94(5):907-15.
  17. Willems HPJ, den Heijer M, Gerrits WBJ, Schurgers LJ, Havekes M, Blom HJ, et al. Oral anticoagulant treatment with coumarin derivates does not influence plasma homocysteine concentration. Eur J Intern Med. 2006;17(2):120-4.
  18. Fallah S, Nourozzi V, Seifi M, Samadikuchaksaraei A, Mokhtaraned Aghadashi E. Influence of oral contraceptive pills on homocysteine and nitric oxide levels: as risk factors of cardiovascular disease. J Clin Lab Anal. 2012;26(2):120-123.
  19. Gatt A, Makris M. Hyperhomocysteinemia and venous thrombosis. Semin Hematol. 2007;44(2):70-6.
  20. Farmer-Boatwright MK, Roubey RAS. Venous thrombosis in the antiphospholipid syndrome. Arterioscler Thromb Vasc Biol. 2009;29(3):321-5.
  21. Naess A, Christiansen SC, Cannegieter SC, Rosendaal FR, Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost. 2006;4(1):44-9.
  22. Lazovic B, Zlatkovic-Svenda M, Jasarovic D, Stevanovic D. Systematic lupus erythematosus presenting as acute lupus pneumonitis. Arch Bronchopneumol. 2018;54(4):222-223.

PDF: 05-MD-Vol 13 No 3-4 Sept-Dec 2021_Dmitrović R. et al..pdf

 

 

Naslovna | Revija | Galerija | Dešavanja | Instrukcije | Redakcija | Izdavač | Prijatelji sajta | Saradnja | Kontakt | Site Map


Back to content | Back to main menu